Oura is facing a proposed class-action lawsuit alleging that the company misled consumers about the accuracy of sleep-stage tracking provided by its smart rings. Filed in the U.S. District Court for the Northern District of California, the complaint challenges Oura's marketing claims around its ability to estimate how much time users spend awake and in light, deep and REM sleep, arguing that consumers may interpret those claims as suggesting accuracy comparable to clinical sleep testing.
The lawsuit argues that Oura Ring does not directly measure the brain activity, eye movements or muscle tone used during polysomnography, the clinical gold standard for assessing sleep stages. Instead, Oura estimates sleep stages using physiological signals captured from the finger, including heart rate, heart rate variability, movement, breathing patterns and temperature. The plaintiff alleges that marketing phrases such as "Built for accuracy," "Unparalleled Accuracy" and claims of 95% sleep-staging accuracy could overstate the technology's capabilities.
The proposed lawsuit seeks to represent consumers nationwide, as well as a California subclass, and includes allegations of fraud by misrepresentation, unjust enrichment, violations of consumer protection laws and breaches of warranty. The plaintiff is seeking damages, restitution and other relief, as well as potential changes to Oura's marketing practices. The claims remain allegations and have not been adjudicated.
Oura disputes the allegations and says it stands behind the scientific evidence supporting its technology. The company emphasizes that its ring is a consumer wearable rather than a medical device or replacement for a clinical sleep study. It says its sleep-stage algorithms have been validated against polysomnography in peer-reviewed research and that multiple independent studies support its accuracy claims.
The dispute highlights a broader challenge for consumer health wearables as increasingly sophisticated algorithms generate health-related insights from indirect physiological signals. As consumers use these measurements to inform decisions about sleep and wellbeing, companies face growing scrutiny over how clearly they distinguish between directly measured data, algorithmic estimates and clinically validated diagnostic information.
Click here to read the original news story.
